Tengion(OTC) TNGNQ

Market Cap$400.00

Since IPO (2010)-100%

5 Year-95%

1 Year+900%

1 Month+900%

$0.00

+0.00%

+0.00Today

Tengion last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-12

Tengion stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+900%	USD 0.00	2026-04-22
1 month	+900%	USD 0.00	2026-04-22
3 month	+900%	USD 0.00	2026-04-22
Year to date	+900%	USD 0.00	2025-12-26
1 year	+900%	USD 0.00	2025-03-28
3 year	+0%	USD 0.00	2023-08-01
5 year	-95%	USD 0.00	2021-08-12
Since inception	-100%	USD 50.20	2010-04-09

Tengion Financials at a Glance

Market Cap

$400.00

Revenue (TTM)

$0.00

Net Income (TTM)

-$72.25M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-16.14 (Low)

Dividend

$0.00

Beta (Volatility)

-16.14 (Low)

Price

$0.00

Volume

1,060

Open

$0.00

Price

$0.00

Volume

1,060

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 18, 2024

Dividend

$0.00

Beta (Volatility)

-16.14 (Low)

Price

$0.00

Volume

1,060

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 18, 2024

TNGNQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tengion

Tengion, Inc. is a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. The company specializes in the discovery, development, and commercialization of advanced cellular therapeutic products, often referred to as "neo-organs."

Products and Services

Neo-Kidney Augment aims to improve kidney function in chronic kidney disease patients
Neo-Urinary Conduit provides an alternative for urinary diversion post-bladder removal
Intellectual property rights in tissue engineering technology

Growth Outlook

Potential market for regenerative medicine is projected to grow significantly
Innovative therapies could address unmet medical needs in chronic conditions
Partnerships may enhance research and development capabilities

Financial Highlights

Recent quarterly net income reported at -$20.2 million
Cash and cash equivalents stood at $5.7 million as of September 30, 2014
Trailing twelve months (TTM) cash flow from operations was negative, indicating ongoing investment needs

Tengion, Inc. has positioned itself in a promising sector with its focus on regenerative medicine. The company's innovative products, such as Neo-Kidney Augment and Neo-Urinary Conduit, aim to address significant health challenges faced by patients with chronic conditions. The growth outlook remains optimistic, driven by the expanding market for regenerative therapies and the potential for strategic partnerships to bolster research and development efforts. Financially, the company has faced challenges, as indicated by its recent net income and cash flow figures. The reported net income of -$20.2 million highlights the ongoing investment in research and development, while the cash position of $5.7 million suggests a need for careful financial management moving forward. Despite these hurdles, the potential for growth in the regenerative medicine market presents an intriguing opportunity for investors interested in innovative healthcare solutions.

AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Winston-Salem, NC 27103, US

TNGNQ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

188.30%

Return on Capital

-164.39%

Return on Assets

-103.21%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$400.00

Shares Outstanding

40.24M

Volume

1.06K

Avg. Volume

16.825

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$18.54M

EBITDA

-$17.19M

Operating Cash Flow

-$19.03M

Capital Expenditure

-$319.00K

Free Cash Flow

-$19.35M

Cash & ST Invst.

$5.73M

Total Debt

$34.12M

Tengion Performance Analysis

Tengion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2013-12-31	N/A
Q1	2014-03-31	N/A
Q2	2014-06-30	N/A
Q3	2014-09-30	N/A

Tengion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2013-12-31	100.0%
Q1	2014-03-31	N/A
Q2	2014-06-30	55.0%
Q3	2014-09-30	12.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2014YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$400.00

N/A

Market Cap/Employee

$16.00

N/A

Employees

N/A

Net Income

-$20.21M

-112.7%

EBITDA

-$4.65M

+6.1%

Quarterly Fundamentals

Name

Q3 2014YOY CHG

Total Cash

$5.73M

-79.2%

Total Debt

$34.12M

+18.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$33.44M

+29.2%

Short Term Debt

$680.00K

-75.9%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.83%

N/A

Free Cash Flow

-$4.40M

+4.5%

Operating Cash Flow

-$4.34M

+5.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CALACalithera Biosciences, Inc.

CALACalithera Biosciences, Inc.$0.00+0.00%

SYVCSynovics Pharmaceuticals, Inc.

SYVCSynovics Pharmaceuticals, Inc.$0.00+0.00%

CMRAComera Life Sciences Holdings, Inc.

CMRAComera Life Sciences Holdings, Inc.$0.00+0.00%

SNNAQSienna Biopharmaceuticals, Inc.

SNNAQSienna Biopharmaceuticals, Inc.$0.00+0.00%

NMRDNemaura Medical Inc.

NMRDNemaura Medical Inc.$0.00+0.00%

XENOXeno Transplants Corporation

XENOXeno Transplants Corporation$0.00+0.00%

KLDOKaleido Biosciences, Inc.

KLDOKaleido Biosciences, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

KHCKraft Heinz

KHCKraft Heinz$24.60+0.01%

ACVAACV Auctions

ACVAACV Auctions$10.41+0.44%

TNONTenon Medical

TNONTenon Medical$5.93+0.12%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$19.16+0.03%

SMRNuScale Power

SMRNuScale Power$8.61-0.16%

NVDANvidia

NVDANvidia$218.29-0.00%

INTCIntel

INTCIntel$102.94+0.03%

Questions About TNGNQ

What is the current price of Tengion?

Tengion is trading at $0.00 per share.

What is the 52-week range for Tengion?

Over the past 52 weeks, Tengion has traded between $0.00 and $0.00.

How much debt does Tengion have?

Tengion total debt is unavailable.

How much cash does Tengion have on hand?

Tengion does not have cash on hand data available.

What is Tengion’s dividend yield?

Tengion does not currently have a dividend yield.

Tengion(OTC) TNGNQ

Tengion Financials at a Glance

TNGNQ News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Tengion

TNGNQ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Tengion Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TNGNQ

What is the current price of Tengion?

What is the 52-week range for Tengion?

How much debt does Tengion have?

How much cash does Tengion have on hand?

What is Tengion’s dividend yield?

Premium Investing Services